[go: up one dir, main page]

DK1382348T3 - Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom - Google Patents

Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom

Info

Publication number
DK1382348T3
DK1382348T3 DK03016996T DK03016996T DK1382348T3 DK 1382348 T3 DK1382348 T3 DK 1382348T3 DK 03016996 T DK03016996 T DK 03016996T DK 03016996 T DK03016996 T DK 03016996T DK 1382348 T3 DK1382348 T3 DK 1382348T3
Authority
DK
Denmark
Prior art keywords
treatment
respiratory disease
vaccine formulation
bovine respiratory
polynucleotide vaccine
Prior art date
Application number
DK03016996T
Other languages
English (en)
Inventor
Jean-Christophe Audonnet
Annabelle Bouchardon
Philippe Baudu
Michel Riviere
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Application granted granted Critical
Publication of DK1382348T3 publication Critical patent/DK1382348T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/813Viral vaccine for bovine species, e.g. cattle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03016996T 1996-07-19 1997-07-16 Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom DK1382348T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609403A FR2751229B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
EP97934578A EP0912194B1 (fr) 1996-07-19 1997-07-16 Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins

Publications (1)

Publication Number Publication Date
DK1382348T3 true DK1382348T3 (da) 2006-03-13

Family

ID=9494497

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03016996T DK1382348T3 (da) 1996-07-19 1997-07-16 Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom
DK97934578T DK0912194T3 (da) 1996-07-19 1997-07-16 Polynucleotid-vaccineformulering, især til behandling af respiratorisk sygdom hos kvæg

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97934578T DK0912194T3 (da) 1996-07-19 1997-07-16 Polynucleotid-vaccineformulering, især til behandling af respiratorisk sygdom hos kvæg

Country Status (28)

Country Link
US (2) US6376473B1 (da)
EP (2) EP1382348B1 (da)
JP (1) JP2000516200A (da)
AP (1) AP9701044A0 (da)
AR (1) AR007862A1 (da)
AT (2) ATE307607T1 (da)
AU (1) AU734442B2 (da)
BR (1) BR9710506A (da)
CA (1) CA2260855C (da)
CO (1) CO4700306A1 (da)
CZ (2) CZ298898B6 (da)
DE (2) DE69725988T2 (da)
DK (2) DK1382348T3 (da)
ES (2) ES2254833T3 (da)
FR (1) FR2751229B1 (da)
HR (1) HRP970383A2 (da)
HU (2) HU225169B1 (da)
ID (1) ID19513A (da)
IL (2) IL127703A0 (da)
MA (1) MA24269A1 (da)
NZ (4) NZ508939A (da)
PE (1) PE84699A1 (da)
PL (1) PL190122B1 (da)
PT (1) PT912194E (da)
RU (1) RU2305560C2 (da)
UA (1) UA70914C2 (da)
WO (1) WO1998003200A2 (da)
ZA (1) ZA976283B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
US6852705B2 (en) * 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
WO2005049794A2 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
EP1718770B1 (en) 2004-02-19 2011-05-25 The Governors of the University of Alberta Leptin promoter polymorphisms and uses thereof
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
BRPI0721630A2 (pt) 2007-05-02 2013-10-15 Merial Ltd Plasmídeo de dna tendo expressão e estabilidade aperfeiçoadas
US8394384B2 (en) 2008-11-28 2013-03-12 Merial Limited Recombinant avian influenza vaccine and uses thereof
MX347997B (es) 2009-04-03 2017-05-22 Merial Ltd Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
WO2011090708A2 (en) 2009-12-28 2011-07-28 Merial Limited Recombinant ndv antigen and uses thereof
ES2678143T3 (es) 2010-01-19 2018-08-09 President And Fellows Of Harvard College Opsonina obtenida por ingeniería genética para la detección y el tratamiento de microorganismos patógenos
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
MA34087B1 (fr) 2010-03-12 2013-03-05 Merial Ltd Vaccins recombinants contre le virus de la langue bleue et leurs utilisations
PL2611460T3 (pl) 2010-08-31 2017-02-28 Merial, Inc. Szczepionki przeciw herpeswirusom przenoszone z pomocą wirusa choroby newcastle
AR084358A1 (es) * 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CN103945864A (zh) 2011-04-25 2014-07-23 先进生物学实验室股份有限公司 截短的hiv包膜蛋白(env)、其相关方法和组合物
EP2714722B1 (en) 2011-05-27 2019-09-11 Boehringer Ingelheim Animal Health USA Inc. Genetic vaccines against hendra virus and nipah virus
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
SG10201608671SA (en) 2011-07-18 2016-12-29 Harvard College Engineered Microbe-Targeting Molecules and Uses Thereof
WO2013025274A1 (en) 2011-08-12 2013-02-21 Merial Limited Vacuum -assisted preservation of biological products, in particular of vaccines
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
US20130177591A1 (en) 2012-01-10 2013-07-11 Merial Limited Lipid Based Adjuvants for DNA Plasmids
WO2013123242A1 (en) 2012-02-14 2013-08-22 Merial Limited Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
EP2814508B1 (en) 2012-02-14 2017-04-12 Merial, Inc. Rotavirus subunit vaccines and methods of making and use thereof
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
ES2664069T3 (es) 2012-06-13 2018-04-18 Merial, Inc. Vacunas contra BTV y AHSV de genoma reordenado
CN109266622B (zh) 2012-08-01 2023-05-09 巴法里安诺迪克有限公司 重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
EP3083658B1 (en) 2013-12-18 2019-05-08 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
ES3050936T3 (en) 2015-06-23 2025-12-23 Boehringer Ingelheim Vetmedica Gmbh Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
EP3331549B1 (en) 2015-08-06 2020-12-23 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
NZ740551A (en) 2015-08-20 2019-10-25 Boehringer Ingelheim Animal Health Usa Inc Fcv recombinant vaccines and uses thereof
RS65084B1 (sr) 2015-09-29 2024-02-29 Boehringer Ingelheim Animal Health Usa Inc Vakcine čestica sličnih virusu (vlp) parvovirusa pasa (cpv) i njihova upotreba
EP3380119B1 (en) 2015-11-23 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Fmdv and e2 fusion proteins and uses thereof
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
CN109021081B (zh) * 2018-08-10 2019-06-04 山东大学 一种牛病毒性腹泻病毒样颗粒及其构建方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010405A1 (en) * 1988-04-22 1989-11-02 The Upjohn Company Chimeric glycoproteins containig immunogenic segments of human parainfluenza virus type 3
NZ239084A (en) * 1990-07-24 1994-09-27 Uab Research Foundation Bovine respiratory virus (brs) f glycoprotein and vaccine therefrom
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
CA2136677A1 (en) * 1993-12-29 1995-06-30 Intervet, Inc. Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5541102A (en) * 1994-09-02 1996-07-30 Board Of Regents, University Of Nebraska-Lincoln Bovine cell line resistant to in vitro infection by bovine viral diarrhea virus and all other known pestiviruses
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6060457A (en) 1996-06-20 2000-05-09 Universite De Montreal DNA plasmid vaccine for immunization of animals against BVDV
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
JP5566663B2 (ja) * 2009-11-09 2014-08-06 三菱重工業株式会社 多翼遠心ファンおよびそれを用いた空気調和機

Also Published As

Publication number Publication date
IL127703A (en) 2006-12-31
CO4700306A1 (es) 1998-12-29
AR007862A1 (es) 1999-11-24
RU2305560C2 (ru) 2007-09-10
FR2751229B1 (fr) 1998-11-27
US6818628B2 (en) 2004-11-16
NZ508939A (en) 2002-04-26
NZ517686A (en) 2003-01-31
ES2254833T3 (es) 2006-06-16
ES2210548T3 (es) 2004-07-01
DE69734483T2 (de) 2006-07-20
HU228353B1 (en) 2013-03-28
PT912194E (pt) 2004-03-31
UA70914C2 (uk) 2004-11-15
WO1998003200A2 (fr) 1998-01-29
NZ508940A (en) 2002-09-27
HU0500910D0 (en) 2005-11-28
PE84699A1 (es) 1999-11-28
CA2260855A1 (en) 1998-01-29
HRP970383A2 (en) 1998-10-31
WO1998003200A3 (fr) 1998-02-26
DE69725988D1 (de) 2003-12-11
HUP9902791A2 (hu) 1999-12-28
EP1382348A2 (fr) 2004-01-21
HU225169B1 (en) 2006-07-28
IL127703A0 (en) 1999-10-28
AU3773597A (en) 1998-02-10
EP0912194B1 (fr) 2003-11-05
RU2002132831A (ru) 2005-01-20
PL190122B1 (pl) 2005-11-30
CZ17599A3 (cs) 1999-06-16
PL331236A1 (en) 1999-07-05
JP2000516200A (ja) 2000-12-05
AP9701044A0 (en) 1997-07-31
MA24269A1 (fr) 1998-04-01
DK0912194T3 (da) 2004-03-15
BR9710506A (pt) 1999-08-17
CZ298898B6 (cs) 2008-03-05
FR2751229A1 (fr) 1998-01-23
EP1382348A3 (fr) 2004-01-28
CA2260855C (en) 2012-01-03
HUP9902791A3 (en) 2000-03-28
DE69725988T2 (de) 2004-11-11
US20020160018A1 (en) 2002-10-31
ID19513A (id) 1998-07-16
DE69734483D1 (de) 2005-12-01
EP0912194A2 (fr) 1999-05-06
AU734442B2 (en) 2001-06-14
EP1382348B1 (fr) 2005-10-26
ATE307607T1 (de) 2005-11-15
ZA976283B (en) 1999-01-19
ATE253376T1 (de) 2003-11-15
NZ333751A (en) 2001-03-30
CZ298915B6 (cs) 2008-03-12
US6376473B1 (en) 2002-04-23

Similar Documents

Publication Publication Date Title
DK1382348T3 (da) Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
DE69734778D1 (de) Polynukleotid-impfstoffformulierung gegen pferdekrankheiten
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
DK0956858T3 (da) Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
DZ2462A1 (fr) Vaccin antigrippal.
DK0912743T3 (da) Polynukleotidvaccinepræparat til behandling af luftvejs- og reproduktionssygdomme hos svin
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
NO996133D0 (no) Olje-i-vann-vaksinesammensetninger
DE69511950D1 (de) Entkuppelbares selbstblockierendes Abseilgerät
FI971732A7 (fi) Rokote ja antitoksiini C. difficilen aiheuttaman taudin hoitamiseksi j a estämiseksi
DE69730839D1 (de) Hühner polynukleotide impfstoff-formulierung
NO991815L (no) Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter
FR2751223B1 (fr) Formule de vaccin polynucleotidique felin
EE04156B1 (et) Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
EE200300214A (et) Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
DZ2283A1 (fr) Composition de vaccin.
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
DE3776999D1 (de) Mittel zur vorbeugung gegen pflanzenviruskrankheiten.
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
NO991459D0 (no) Anvendelse av 1-hydroksy-2-pyridoner til behandling av hudinfeksjoner
DE60032884D1 (de) Blutbehandlungssystem
DE69737067D1 (de) Vakzine zur behandlung von mycosen
BR9806083A (pt) Composi-Æo farmac-utica para o tratamento da hapattite c